Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves First-Ever Treatment for Thyroid Eye Disease

By Mark Prvulovic - Jan 21, 2020 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Patients with this rare condition can now get relief for their symptoms.

The Food and Drug Administration (FDA) announced on Tuesday that it had just approved the first-ever treatment for thyroid eye disease (TED), Tepezza, which is developed by Horizon Therapeutics (HZNP 0.15%).

Thyroid eye disease, also known as Graves' ophthalmopathy, is a rare disease that, according to some sources, affects as many as 42 people per 100,000 every year. This rare condition causes the tissues behind the eye to become inflamed, which results in the eye becoming red and swollen, and causes severe problems such as double vision.

A close-up of a person's left eye.

Image source: Getty Images.

In addition to receiving approval to treat TED, Tepezza also received Priority Review, Orphan Drug, Fast Track, and Breakthrough Therapy designations from the agency.

A big deal for a rare disease

Previous clinical trial results for Tepezza include a phase 2 trial done in 2017, as well as a more recent phase 3 trial. The latter trial saw a significant improvement in patients with TED in comparison to the placebo, with symptoms of the condition -- such as double vision -- seeing a significant reduction in severity.

Tepezza was the subject of an FDA advisory committee meeting back in December, with the committee voting unanimously in favor of Tepezza's approval. Although the pharmaceutical company has received approval alongside a slew of designations from the agency following the decision, Horizon will still conduct a post-marketing study on a larger patient population to further evaluate the safety of the drug. The most common side effects include muscle spasms and nausea, which were relatively mild during the clinical trials.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$81.81 (0.15%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.